Table 2 Baseline data of the patients in the training group

Patients’ number

64

22

-

23

15

-

-

Age (y)

56 (Q1: 48; Q3: 60)

56 (Q1: 50; Q3: 60)

0.905

58.6 ± 11.3

52.7 ± 8.6

0.075

0.41

BMI

22.5 ± 2.8

22.8 ± 2.8

0.671

22.9 ± 2.4

21.8 ± 2.2

0.147

0.729

Differentiation

0.001

0.059

0.066

 Poor

4 (6.3%)

9 (40.9%)

4 (17.4%)

7 (46.7%)

 Moderate

25 (39.0%)

11 (50%)

11 (47.8%)

7 (47.7%)

 Well

35 (54.7%)

2 (9.1%)

8 (34.8%)

1 (6.6%)

Cervical stromal invasion depth

0.017

0.335

0.138

 < 1/2

41 (64.1%)

7 (31.8%)

11 (47.8%)

4 (26.7%)

 ≥ 1/2

23 (35.9%)

15 (68.2%)

12 (52.2%)

11 (73.3%)

SCC

0.186

0.294

0.782

 < 2.5 μg/L

20 (31.3%)

11 (50%)

9 (39.1%)

3 (20%)

 ≥ 2.5 μg/L

44 (68.7%)

11 (50%)

14 (60.9%)

12 (80%)

Ca199

0.748

0.138

0.574

 < 37 U/L

54 (84.4%)

18 (81.8%)

19 (82.6%)

15 (100%)

 ≥ 37 U/L

10 (15.6%)

4 (18.2%)

4 (17.4%)

0 (0%)

AFP

0.101

0.063

1.000

 < 7 μg/L

50 (78.1%)

21 (95.5%)

17 (73.9%)

15 (100%)

 ≥ 7 μg/L

14 (21.9%)

1 (4.5%)

6 (26.1%)

0 (0%)

CEA

0.759

0.223

1.000

 < 5 μg/L

52 (81.3%)

17 (77.3%)

20 (87.0%)

10 (66.7%)

 ≥ 5 μg/L

12 (18.7%)

5 (22.7%)

3 (13.0%)

5 (33.3%)

FIGO stage

0.001

0.591

1.000

 I

38 (59.4%)

4 (18.2%)

11 (47.8%)

7 (46.7%)

 II

23 (39.1%)

16 (72.7%)

12 (52.2%)

7 (46.7%)

 III

1 (1.5%)

2 (9.1%)

0 (0%)

1 (6.6%)

Cancer types

0.843

0.114

0.561

 Adenocarcinoma

17 (26.6%)

7 (31.8%)

7 (30.4%)

1 (6.6%)

 Others

47 (74.4%)

15 (68.2%)

16 (69.6%)

14 (93.4)